Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Operating Expenses: 2015-2024

Historic Operating Expenses for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $121.3 million.

  • Seres Therapeutics' Operating Expenses fell 21.74% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.8 million, marking a year-over-year decrease of 19.86%. This contributed to the annual value of $121.3 million for FY2024, which is 37.82% down from last year.
  • As of FY2024, Seres Therapeutics' Operating Expenses stood at $121.3 million, which was down 37.82% from $195.1 million recorded in FY2023.
  • Over the past 5 years, Seres Therapeutics' Operating Expenses peaked at $209.4 million during FY2021, and registered a low of $121.3 million during FY2024.
  • Moreover, its 3-year median value for Operating Expenses was $179.9 million (2022), whereas its average is $165.4 million.
  • Per our database at Business Quant, Seres Therapeutics' Operating Expenses skyrocketed by 72.58% in 2021 and then slumped by 37.82% in 2024.
  • Over the past 5 years, Seres Therapeutics' Operating Expenses (Yearly) stood at $121.3 million in 2020, then spiked by 72.58% to $209.4 million in 2021, then dropped by 14.09% to $179.9 million in 2022, then increased by 8.44% to $195.1 million in 2023, then tumbled by 37.82% to $121.3 million in 2024.